Evidence map›Paper›PMID 32695229›Full record

Trial reportCardiovascular therapeutics2020

Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol.

Roland Gal, Dora Praksch, Peter Kenyeres, Miklos Rabai, Kalman Toth, Robert Halmosi, Tamas Habon

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Roland GalDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.ORCID https://orcid.org/0000-0003-4029-7913
Dora PrakschDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.ORCID https://orcid.org/0000-0001-7430-1402
Peter KenyeresDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.
Miklos RabaiDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.
Kalman TothDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.
Robert HalmosiDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.
Tamas HabonDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, Hungary.ORCID https://orcid.org/0000-0002-4816-857X
University of Pecs · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSeveral beneficial effects of resveratrol have already been published. This study evaluated the effect of resveratrol on the hemorheological parameters in patients with heart failure with reduced ejection fraction.

methodsIn our double-blind, placebo-controlled human clinical trial, we enrolled 60 outpatients with heart failure. Patients were randomized into two groups: receiving either 100 mg resveratrol capsule daily or placebo for 3 months. Hematocrit was determined by microhematocrit centrifuge. Plasma and whole blood viscosity was evaluated by capillary viscometer. Erythrocyte aggregation was measured by both LORCA and Myrenne aggregometers. LORCA ektacytometer was used for measuring erythrocyte deformability. Exercise capacity was assessed by a 6-minute walk test.

resultsResveratrol treatment did not have any significant effect on hematocrit and viscosity. The erythrocyte deformability also remained unchanged. However, significant improvement of red blood cell aggregation was observed in the resveratrol group compared to baseline after 3 months. Furthermore, positive correlation was found between the exercise capacity and the hemorheological properties (Hct, WBV, and RBC aggregation and deformability) as well.

conclusionThese findings indicate that resveratrol can significantly reduce red blood cell aggregation, which may positively influence microcirculation, which may contribute to the improvement of tissue perfusion and oxygen supply in heart failure.

Indexed as

AgedCardiovascular AgentsDouble-Blind MethodErythrocyte AggregationExercise ToleranceFemaleHeart FailureHumansHungaryMaleMiddle AgedResveratrolStroke VolumeTime FactorsTreatment OutcomeVentricular Function, LeftCardiovascular AgentsResveratrol

Identifiers

PMID32695229
PMCPMC7350166
OpenAlexW3038759215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.